Quality -of-life scores ( Piper Fatigue Scale MD 0.73 , 95 % CI 0.29 to 1.18 ; I2 = 0 % ; studies = 3 ) and peak oxygen consumption ( MD 2.77 mL/kg/min , 95 % CI -0.89 to 6.43 ; I2 = 36 % ; 2 studies , 32 participants ) were associated with very low- quality evidence , and we remain uncertain about the role of intravenous iron for these metrics .
Current evidence is insufficient to show benefit of intravenous iron preparations for the treatment of non-anaemic iron deficiency across a variety of patient population s , beyond stating that it may result in a small , clinical ly insignificant increase in haemoglobin concentration .
BACKGROUND Iron deficiency is one of the most common nutritional deficiencies , and has a number of physiological manifestations .
Early , or non-anaemic iron deficiency can result in fatigue and diminished exercise capacity .
Oral iron preparations have a high incidence of intolerable side effects , and are ineffective in certain forms of iron deficiency .
Consequently , intravenous iron preparations are increasingly used in the treatment of non-anaemic iron deficiency .
The newer , more stable iron preparations in particular purport to have a lower incidence of side effects , and are now used across a range of different patient population s. OBJECTIVES To assess the effects of intravenous iron therapy in the treatment of adults with non-anaemic iron deficiency .
Comparison of short-term efficacy of iron sucrose with those of ferric chloride in hemodialysis patients: An open-label study
Background : It is intriguing and imperative that the comparison of the iron preparations in hemodialysis ( HD ) patients . This study aim ed to observe the short-term efficacy of parenteral iron sucrose and ferric chloride in HD patients . Material s and Methods : This was a consecutive 10-week single-blind study in Taiwan . An intravenous iron supplement of 100 mg/week was administered as an infusion in 100 ml of normal saline , until a total dose of 1000 mg was achieved . The primary outcome was evaluated by the changes in serum hematocrit ( Hct ) levels . The changes in serum Hct and iron indices were evaluated every 2 weeks for 10 weeks . The results were collected from 21 April to 4 July 2013 . Results : A total of 56 HD patients completed the study . Subjects were r and omized into an iron sucrose group ( 26 patients ) and a ferric chloride group ( 30 patients ) . Between the two treatment groups , there were no statistically significant differences in the change in serum Hct , ferritin , iron , or total iron binding capacity ( P > 0.05 ) . In the iron sucrose group , the increase in Hct levels was statistically significant at weeks 4 , 8 , and 10 . In the ferric chloride group , the increase in Hct levels was statistically significant at week 8 . No obvious major side effects were observed in both groups . Conclusion : In the study subjects , parenteral iron sucrose was as effective and safe as ferric chloride for treating anemia in HD patients
Quality -of-life scores ( Piper Fatigue Scale MD 0.73 , 95 % CI 0.29 to 1.18 ; I2 = 0 % ; studies = 3 ) and peak oxygen consumption ( MD 2.77 mL/kg/min , 95 % CI -0.89 to 6.43 ; I2 = 36 % ; 2 studies , 32 participants ) were associated with very low- quality evidence , and we remain uncertain about the role of intravenous iron for these metrics .
Current evidence is insufficient to show benefit of intravenous iron preparations for the treatment of non-anaemic iron deficiency across a variety of patient population s , beyond stating that it may result in a small , clinical ly insignificant increase in haemoglobin concentration .
BACKGROUND Iron deficiency is one of the most common nutritional deficiencies , and has a number of physiological manifestations .
Early , or non-anaemic iron deficiency can result in fatigue and diminished exercise capacity .
Oral iron preparations have a high incidence of intolerable side effects , and are ineffective in certain forms of iron deficiency .
Consequently , intravenous iron preparations are increasingly used in the treatment of non-anaemic iron deficiency .
The newer , more stable iron preparations in particular purport to have a lower incidence of side effects , and are now used across a range of different patient population s. OBJECTIVES To assess the effects of intravenous iron therapy in the treatment of adults with non-anaemic iron deficiency .